CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 38,942	$ 7,784
General and administrative	3,784	2,848
Total operating expenses	42,726	10,632
Loss from operations	(42,726)	(10,632)
Interest income	848	5
Interest expense		(21)
Australian research and development incentives	272	37
Foreign currency gain (loss)	(307)	235
Change in fair value of Series X preferred stock warrant liability	50
Net loss attributable to common stockholders	$ (41,863)	$ (10,376)
Net loss per share
Basic	$ (0.32)	$ (0.09)
Diluted	$ (0.32)	$ (0.09)
Weighted average common shares outstanding
Basic	129,344,272	113,248,937
Diluted	129,344,272	113,248,937